Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4785845
Max Phase: Preclinical
Molecular Formula: C29H26ClF4N5O3
Molecular Weight: 604.00
Molecule Type: Unknown
Associated Items:
ID: ALA4785845
Max Phase: Preclinical
Molecular Formula: C29H26ClF4N5O3
Molecular Weight: 604.00
Molecule Type: Unknown
Associated Items:
Canonical SMILES: O=C(C[C@@H]1Cc2cc(Cl)c3[nH]ncc3c2CN(CC(F)(F)F)C1=O)N1CCC(c2cc3cccc(F)c3[nH]c2=O)CC1
Standard InChI: InChI=1S/C29H26ClF4N5O3/c30-22-10-17-8-18(28(42)39(14-29(32,33)34)13-21(17)20-12-35-37-26(20)22)11-24(40)38-6-4-15(5-7-38)19-9-16-2-1-3-23(31)25(16)36-27(19)41/h1-3,9-10,12,15,18H,4-8,11,13-14H2,(H,35,37)(H,36,41)/t18-/m0/s1
Standard InChI Key: UURYPVBRRAPKHX-SFHVURJKSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 604.00 | Molecular Weight (Monoisotopic): 603.1660 | AlogP: 5.06 | #Rotatable Bonds: 4 |
Polar Surface Area: 102.16 | Molecular Species: NEUTRAL | HBA: 4 | HBD: 2 |
#RO5 Violations: 2 | HBA (Lipinski): 8 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 9.97 | CX Basic pKa: 1.62 | CX LogP: 3.56 | CX LogD: 3.56 |
Aromatic Rings: 4 | Heavy Atoms: 42 | QED Weighted: 0.32 | Np Likeness Score: -0.92 |
1. Mercer SE,Chaturvedula PV,Conway CM,Cook DA,Davis CD,Pin SS,Macci R,Schartman R,Signor LJ,Widmann KA,Whiterock VJ,Chen P,Xu C,Herbst JJ,Kostich WA,Thalody G,Macor JE,Dubowchik GM. (2021) Azepino-indazoles as calcitonin gene-related peptide (CGRP) receptor antagonists., 31 [PMID:33096162] [10.1016/j.bmcl.2020.127624] |
Source(1):